{"prompt": "['Product: MK-3475', '95', 'Protocol/Amendment No.: 604-09', 'Such events must be reported within 24 hours to the Sponsor either by electronic media or', 'paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper', 'reporting procedures can be found in the Investigator Trial File Binder (or equivalent).', '7.2.3 Immediate Reporting of Adverse Events to the Sponsor', '7.2.3.1 Serious Adverse Events', \"An SAE is any AE occurring at any dose or during any use of Sponsor's product that:\", 'Results in death;', 'Is life-threatening;', 'Results in persistent or significant disability/incapacity;', 'Results in or prolongs an existing inpatient hospitalization;', 'Is a congenital anomaly/birth defect;', 'Is another important medical event.', '*Note: In addition to the above criteria, AEs meeting either of the below criteria,', 'although not serious per ICH definition, are reportable to the Sponsor in the same', 'timeframe as SAEs to meet certain local requirements. Therefore, these events are', 'considered serious by the Sponsor for collection purposes.', 'Is a new cancer (that is not a condition of the study);', 'Is associated with an overdose.', 'Refer to Table 10 for additional details regarding each of the above criteria.', 'For the time period beginning when the consent form is signed until treatment', 'allocation/randomization, any SAE, or follow up to an SAE, including death due to any cause', 'other than progression of the cancer under study (see Section 7.2.3.3 for additional details),', 'that occurs to any subject must be reported within 24 hours to the Sponsor if it causes the', 'subject to be excluded from the trial, or is the result of a protocol-specified intervention,', 'including but not limited to washout or discontinuation of usual therapy, diet, placebo', 'treatment or a procedure.', 'For the time period beginning at treatment allocation/randomization through 90 days', 'following cessation of trial treatment, or 30 days following cessation of trial treatment if the', 'subject initiates new anticancer therapy, whichever is earlier, any SAE, or follow up to a', 'SAE, including death due to any cause other than progression of the cancer under study (see', \"Section 7.2.3.3 for additional details), whether or not related to the Sponsor's product, must\", 'be reported within 24 hours to the Sponsor either by electronic media or paper. Electronic', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '96', 'Protocol/Amendment No.: 604-09', 'reporting procedures can be found in the EDC data entry guidelines. Paper reporting', 'procedures can be found in the Investigator Trial File Binder (or equivalent).', 'Additionally, any SAE, considered by an investigator who is a qualified physician to be', \"related to the Sponsor's product that is brought to the attention of the investigator at any time\", 'following consent through the end of the specified safety follow-up period specified in the', 'paragraph above, or at any time outside of the time period specified in the previous paragraph', 'also must be reported immediately to the Sponsor.', 'All subjects with SAEs must be followed up for outcome.', '7.2.3.2 Events of Clinical Interest', 'Selected non-serious and serious adverse events are also known as Events of Clinical Interest', '(ECI) and must be reported to the Sponsor.', 'For the time period beginning when the consent form is signed until treatment', 'allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be', 'reported within 24 hours to the Sponsor if it causes the subject to be excluded from the trial,', 'or is the result of a protocol-specified intervention, including but not limited to washout or', 'discontinuation of usual therapy, diet, placebo treatment or a procedure.', 'For the time period beginning at treatment allocation/randomization through 30 days', 'following cessation of treatment, any ECI, or follow up to an ECI, whether or not related to', \"the Sponsor's product, must be reported within 24 hours to the Sponsor, either by electronic\", 'media or paper. Electronic reporting procedures can be found in the EDC data entry', 'guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or', 'equivalent).', 'Events of clinical interest for this trial include:', \"an overdose of Sponsor's product, as defined in Section 7.2.1 - Definition of an\", 'Overdose for This Protocol and Reporting of Overdose to the Sponsor, that is not', 'associated with clinical symptoms or abnormal laboratory results.', 'an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit', 'of normal and an elevated total bilirubin lab value that is greater than or equal to 2X', 'the upper limit of normal and, at the same time, an alkaline phosphatase lab value that', 'is less than 2X the upper limit of normal, as determined by way of protocol-specified', 'laboratory testing or unscheduled laboratory testing.*', '*Note: These criteria are based upon available regulatory guidance documents. The', 'purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require', 'an additional evaluation for an underlying etiology. The trial site guidance for assessment', 'and follow up of these criteria can be found in the Investigator Trial File Binder (or', 'equivalent).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}